Oragenics Inc (OGEN) Stock Price, Quote & News

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain...

Industry: Biotechnology

Sector: Healthcare

Phone: 813 286 7900

Website: www.oragenics.com

Address:

9015 Town Center Parkway, Suite 143, Lakewood Ranch, United States

Gev222 Sep. 16 at 8:58 PM

$OGEN only thing green today

0 · Reply

NMax Sep. 16 at 7:21 PM

$OGEN Looking forward to that fraud and future convicted felon Rocketqueen, to claim he bought back in. 😁😆 Continuing to accumulate in the meantime!!😁 🤑🤑🤑

0 · Reply

focafoca99 Sep. 16 at 6:43 PM

$OGEN set its CMO to present at the IPAC-RS 2026 Nasal Innovation Forum on Sep 17. https://www.rapidticker.com/news/ogen-sec-filing-396210

0 · Reply

RocketQueen Sep. 16 at 4:19 PM

$OGEN FEDS to raise interest rates. Would not be surprised to see this drop soon.

0 · Reply

NMax Sep. 15 at 8:34 PM

$OGEN Yeah...so anyways... Continuing to accumulate!! 🤑🤑🤑

0 · Reply

RocketQueen Sep. 15 at 12:51 AM

$OGEN pure trash stock. Not much going to happen here except possible delisting and reverse split.

0 · Reply

NMax Sep. 14 at 12:42 PM

$OGEN So much whining from accounts that claim to hold no shares!! 🤣🤣 Anyways. Continuing to accumulate!! 🤑🤑🤑

0 · Reply

RocketQueen Sep. 14 at 11:50 AM

$OGEN failed company that's facing possible delisting due to non-compliance of the market cap.-

0 · Reply

profitingstocks Sep. 12 at 10:11 AM

$OGEN if you invested $25,000 in this stock at the start of 2017 hoping for a long play, you’d have less than $1 left today

0 · Reply

NMax Sep. 11 at 11:25 PM

$OGEN These idiots that claim to hold no shares sure do whine a lot. 🤣 Anyway, looking forward to accumulating more next week!!! Seeya then!! 🤑🤑🤑

0 · Reply

Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum

Aug 28, 2026, 4:25 PM EDT - 19 days ago

Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

Jul 7, 2026, 8:30 AM EDT - 2 months ago

Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling

May 19, 2026, 8:45 AM EDT - 4 months ago

Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21

May 18, 2026, 8:30 AM EDT - 4 months ago

ORAGENICS PROVIDES INVESTOR UPDATE

May 7, 2026, 8:30 AM EDT - 4 months ago

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

May 5, 2026, 8:30 AM EDT - 4 months ago

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

2026-04-20T14:01:13.000Z - 4 months ago

Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002

Apr 13, 2026, 8:30 AM EDT - 5 months ago

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

2026-03-25T22:35:16.000Z - 5 months ago

Oragenics receives audit opinion with going concern explanation

Mar 25, 2026, 6:30 PM EDT - 5 months ago

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

2026-03-17T12:49:42.000Z - 6 months ago

Oragenics files annual report on Form 10-K

2026-03-12T12:48:45.000Z - 6 months ago

Oragenics initiates Phase IIa clinical trial site activation

Mar 12, 2026, 8:30 AM EDT - 6 months ago

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

2026-03-11T12:45:33.000Z - 6 months ago

Oragenics explores potential acquisition of additional assets in CNS space

Mar 11, 2026, 8:30 AM EDT - 6 months ago

ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

2026-03-10T12:42:00.000Z - 6 months ago

Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia

Mar 10, 2026, 8:30 AM EDT - 6 months ago

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

2026-02-09T13:46:12.000Z - 7 months ago

Oragenics previews targeted milestones for 2026

Feb 9, 2026, 8:30 AM EST - 7 months ago

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

2026-02-03T13:40:46.000Z - 7 months ago

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

Feb 3, 2026, 8:30 AM EST - 7 months ago

Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

2026-01-22T21:15:38.000Z - 7 months ago

Oragenics files $100M mixed securities shelf

Nov 12, 2025, 8:30 AM EST - 10 months ago

Oragenics Q3 2025 Shareholder Update

2025-10-21T12:15:12.000Z - 11 months ago

Oragenics regains compliance with NYSE

Oct 21, 2025, 8:00 AM EDT - 11 months ago

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

2025-10-07T13:20:29.000Z - 11 months ago

Oragenics, Receptor.AI partner to accelerate pipeline development

Oct 7, 2025, 8:30 AM EDT - 11 months ago

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

2025-08-11T12:50:19.000Z - 1 year ago

Oragenics reports Q2 EPS ($3.10) vs. ($15.27) last year.

Aug 11, 2025, 8:45 AM EDT - 1 year ago

Oragenics Q2 2025 Shareholder Update

2025-07-31T12:52:03.000Z - 1 year ago

Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial

2025-07-16T12:45:56.000Z - 1 year ago

Oragenics announces manufacturing agreement with Sterling Pharma for ONP-002

Jul 16, 2025, 8:39 AM EDT - 1 year ago

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Jul 2, 2025, 4:15 PM EDT - 1 year ago

Oragenics Completes Approximately $16.5 Million Offering

2025-07-02T01:00:00.000Z - 1 year ago

Why Is Oragenics Stock (OGEN) Down 55% Today?

2025-07-01T12:50:11.000Z - 1 year ago

Oragenics trading resumes

2025-07-01T12:41:48.000Z - 1 year ago

Oragenics prices 800,000 shares of Preferred Stock at $25.00 in public offering

Jul 1, 2025, 8:31 AM EDT - 1 year ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

2025-07-01T12:05:53.000Z - 1 year ago

Oragenics trading halted, news pending

2025-06-03T13:40:31.000Z - 1 year ago

Oragenics trading resumes

May 13, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 12, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Apr 7, 2025, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 18, 2025, 5:33 PM EDT - 1 year ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 6, 2025, 9:30 AM EST - 1 year ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Feb 25, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 11, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 5, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Jan 21, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Dec 16, 2024, 8:09 AM EST - 1 year ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Sep 5, 2024, 4:30 PM EDT - 2 years ago

Oragenics, Inc. Announces Closing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 2 years ago

Oragenics, Inc. Announces Pricing of Public Offering

Aug 21, 2024, 8:45 AM EDT - 2 years ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 16, 2024, 4:30 PM EDT - 2 years ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 8, 2024, 8:45 AM EDT - 2 years ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 24, 2024, 6:43 PM EDT - 2 years ago

Oragenics, Inc. Announces Proposed Public Offering

May 22, 2024, 8:00 AM EDT - 2 years ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 17, 2024, 8:00 AM EDT - 2 years ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Apr 19, 2024, 5:50 PM EDT - 2 years ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 1, 2024, 9:05 AM EDT - 2 years ago

Oragenics, Inc. Files 10K and Provides Company Update

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 5, 2024, 7:45 AM EST - 2 years ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Gev222 Sep. 16 at 8:58 PM

$OGEN only thing green today

0 · Reply

NMax Sep. 16 at 7:21 PM

$OGEN Looking forward to that fraud and future convicted felon Rocketqueen, to claim he bought back in. 😁😆 Continuing to accumulate in the meantime!!😁 🤑🤑🤑

0 · Reply

focafoca99 Sep. 16 at 6:43 PM

$OGEN set its CMO to present at the IPAC-RS 2026 Nasal Innovation Forum on Sep 17. https://www.rapidticker.com/news/ogen-sec-filing-396210

0 · Reply

RocketQueen Sep. 16 at 4:19 PM

$OGEN FEDS to raise interest rates. Would not be surprised to see this drop soon.

0 · Reply

NMax Sep. 15 at 8:34 PM

$OGEN Yeah...so anyways... Continuing to accumulate!! 🤑🤑🤑

0 · Reply

RocketQueen Sep. 15 at 12:51 AM

$OGEN pure trash stock. Not much going to happen here except possible delisting and reverse split.

0 · Reply

NMax Sep. 14 at 12:42 PM

$OGEN So much whining from accounts that claim to hold no shares!! 🤣🤣 Anyways. Continuing to accumulate!! 🤑🤑🤑

0 · Reply

RocketQueen Sep. 14 at 11:50 AM

$OGEN failed company that's facing possible delisting due to non-compliance of the market cap.-

0 · Reply

profitingstocks Sep. 12 at 10:11 AM

$OGEN if you invested $25,000 in this stock at the start of 2017 hoping for a long play, you’d have less than $1 left today

0 · Reply

NMax Sep. 11 at 11:25 PM

$OGEN These idiots that claim to hold no shares sure do whine a lot. 🤣 Anyway, looking forward to accumulating more next week!!! Seeya then!! 🤑🤑🤑

0 · Reply

RocketQueen Sep. 11 at 9:41 PM

$OGEN newly minted ATL: Janet: .48/30 = .016, Kim: .016/60 = .00026 , Good job ladies.

0 · Reply

profitingstocks Sep. 11 at 9:15 PM

$OGEN new all time low

0 · Reply

NMax Sep. 11 at 6:06 PM

$OGEN Yeah...so anyways... Continuing to accumulate...next week!! Have fun washing those shares for me in the meantime lol 😆 🤑🤑🤑

0 · Reply

RocketQueen Sep. 11 at 12:47 AM

$OGEN today volume was 9,235.00. This is trading like a company about to either get delisted or go bankrupt.

0 · Reply

NMax Sep. 10 at 3:08 PM

$OGEN Yeah...so anyways... Continuing to accumulate!! 🤑🤑🤑

0 · Reply

RocketQueen Sep. 10 at 2:46 PM

$OGEN scam and fraud company. All time gain for retail investors is -100%

0 · Reply

RocketQueen Sep. 10 at 11:49 AM

$OGEN programs targeting rare diseases?? If the diseases are rare, then there is no addressable market for investors. The long time loss for investors is 100% here. The longer they keep the lights on, the larger the eventual lawsuit.

0 · Reply

RocketQueen Sep. 10 at 12:44 AM

$OGEN volume is drying up here. Today was 5,353.00

0 · Reply

danielmaia12 Sep. 9 at 8:15 PM

$OGEN Has programs targeting rare diseases and neurodegenerative conditions…

0 · Reply

RocketQueen Sep. 9 at 6:13 PM

$OGEN a miracle this is still trading above fifty cents, but without any volume nothing is solid. Notice right now, the volume is only 1,428.00. Basically, investors have abandoned this company because they are way past seeing this as a scam to pay Janet's salary and the board's slush fund. Look at their long term record with no evidence of producing anything. Even the crappiest penny stocks have produced some product for sale. Oragenics has nothing.

0 · Reply

NMax Sep. 8 at 4:05 PM

$OGEN All these idiotic accounts that have already sold are becoming so active despite have no shares. How bizarre! 🤔 anyways... Continuing to accumulate!! 🤑🤑🤑

0 · Reply

RocketQueen Sep. 8 at 4:05 PM

$OGEN will they pivot to another trash can pivot after the nasal scam is brought to light in the data readout? They offer no products or benefit to society and so just pure loss here. There is no point to testing a product developed by a criminal awaiting sentencing for prison. That's irresponsible to shareholders.

0 · Reply

Market Cap	2.20M
Revenue (ttm)	0.00
Net Income (ttm)	-9.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	54,700
Avg Vol	28,978
Day's Range	N/A - N/A
Shares Out	4.51M
Stochastic %K	51%
Beta	1.25
Analysts	Strong Buy
Price Target	$2.00